FHTX Key Statistics, Chart & Performance
The current stock price of FHTX is 4.75 USD. In the past month the price increased by 10.21%. In the past year, price decreased by -40.55%.
FHTX Latest News, Press Relases and Analysis
FHTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 185.98B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.15B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.98B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About FHTX
Company Profile
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2020-10-23. The firm is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The firm is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Company Info
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139 US
CEO: Adrian Gottschalk
Employees: 112
Phone: 16175863100
FOGHORN THERAPEUTICS INC / FHTX FAQ
Can you describe the business of FOGHORN THERAPEUTICS INC?
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2020-10-23. The firm is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The firm is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
What is the current price of FHTX stock?
The current stock price of FHTX is 4.75 USD. The price decreased by -1.25% in the last trading session.
Does FHTX stock pay dividends?
FHTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of FHTX stock?
FHTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of FHTX stock?
FOGHORN THERAPEUTICS INC (FHTX) operates in the Health Care sector and the Biotechnology industry.
Is FOGHORN THERAPEUTICS INC (FHTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FHTX.
What is the outstanding short interest for FOGHORN THERAPEUTICS INC?
The outstanding short interest for FOGHORN THERAPEUTICS INC (FHTX) is 1.7% of its float.
FHTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to FHTX. When comparing the yearly performance of all stocks, FHTX is a bad performer in the overall market: 86.11% of all stocks are doing better.
FHTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FHTX. FHTX has a bad profitability rating. Also its financial health evaluation is rather negative.
FHTX Financial Highlights
Over the last trailing twelve months FHTX reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 41.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.19% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FHTX Forecast & Estimates
13 analysts have analysed FHTX and the average price target is 11.95 USD. This implies a price increase of 151.55% is expected in the next year compared to the current price of 4.75.
For the next year, analysts expect an EPS growth of 26.44% and a revenue growth 2.76% for FHTX